ClinicalTrials.gg
CompletedNCT06153238Updated Jul 7, 2026

A PK Study to Compare GME751 (Proposed Pembrolizumab Biosimilar) and US-licensed and EU-authorized Keytruda® in Participants With Stage II and III Melanoma

A Phase 1 interventional study of GME751 and Keytruda - EU in Melanoma, sponsored by Sandoz. Completed at 61 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-07.

Sponsored by Sandoz (formerly part of Novartis) · Phase 1, Interventional, and Treatment

How we know · 4 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
322
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 51 studies in Melanoma by Novartis — 1 open to participants now, 6 under way, none of them phase 3. Melanoma · Novartis.

Enrollment
8th of 35
322 · median 134
Started
2024
the only one that year
Phase 1
11 of 51
none open now
Registered
47th of 51
by date

Among the 51 studies in Melanoma by Novartis, this one is the 8th largest by enrollment of the 35 interventional ones that give a count, is the only one that started in 2024, is one of 11 in phase 1, and was the 47th registered.

Melanoma

3,374 studies on the registry are indexed under Melanoma; 579 are open to participants now.

Browse Melanoma studies →

Open to participants now

1 of the 51 studies in Melanoma by Novartis is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 467 Melanoma studies recruiting now, 379 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies in Melanoma by Novartis, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the pharmacokinetic (PK) similarity and efficacy, safety, and immunogenicity of GME751 compared with Keytruda® (pembrolizumab) in subjects with resected advanced melanoma requiring adjuvant treatment with pembrolizumab.

Read the detailed description

Eligible subjects will be randomized in a 1:1:1 ratio to receive either GME751, Food and Drug Administration (FDA)-licensed pembrolizumab (Keytruda-US) or European Union (EU)-authorized pembrolizumab (Keytruda-EU). The maximum study duration for a participant will be approximately 28 weeks including screening.

Treatment duration is 24 weeks (4 treatment cycles, each of 6 weeks duration). However, subject should discontinue study participation in case of disease recurrence, unacceptable toxicity or other reasons.

Participants who are benefiting from treatment with pembrolizumab without signs of recurrence or unacceptable toxicity will be eligible for continued pembrolizumab treatment via most suitable option based on the respective country regulations.

03

Conditions studied

  • Melanoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least 18 years of age
  • Advanced Melanoma
  • Completely removed melanoma by surgery performed within 13 weeks of randomization
  • Adequate organ function
  • Subject has an (ECOG) performance status score of 0 or 1

Exclusion criteria

Exclusion Criteria:

  • Known history or evidence of ocular or uveal melanoma
  • Known history of (grade ≥3) to pembrolizumab or its
  • Known History of auto-immune disease
  • Received ≤30 days before the first study treatment
  • Prior treatment with agents or agent against another stimulatory or co-inhibitory T cell receptor
  • Active disease that has necessitated chronic systemic treatment within 2 years before the first study treatment

Other protocol-defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
322 participants (actual)

Study arms

  • Experimental
    GME751

    Subjects will receive GME751 via intravenous (IV) infusion.

    Drug: GME751

  • Active comparator
    Keytruda - EU

    Subjects will receive Keytruda-EU via intravenous (IV) infusion.

    Drug: Keytruda - EU

  • Active comparator
    Keytruda - US

    Subjects will receive Keytruda-US via intravenous (IV) infusion.

    Drug: Keytruda - US

Interventions

  • DrugGME751

    400 mg Q6W, i.v. infusion, over 24 weeks period

  • DrugKeytruda - EU

    400 mg Q6W, i.v. infusion, over 24 weeks period

  • DrugKeytruda - US

    400 mg Q6W, i.v. infusion, over 24 weeks period

06

What researchers measure

Primary outcomes

  1. Area Under the Serum Concentration-time Curve from Time Zero to 42 Days (AUC0-42d)

    The PK similarity (AUC0-42d) of GME751 compared with pembrolizumab will be demonstrated in subjects with advanced melanoma in the adjuvant setting.

    Time frame: Day 1 (Postdose) through Day 42

  2. Area Under the Serum Concentration-time Curve Over the Dosing Interval at Steady State

    The PK similarity (AUCtau\_ss) of GME751 compared with pembrolizumab will be demonstrated in subjects with advanced melanoma in the adjuvant setting.

    Time frame: Week 19 through Week 24

07

Study locations

61 sites
  • Sandoz Investigational Site
    Orange, California 92868, United States
  • Sandoz Investigational Site
    Clermont, Florida 34711, United States
  • Sandoz Investigational Site
    Orange City, Florida 32763, United States
  • Sandoz Investigational Site
    Banja Luka, Bosnia and Herzegovina
  • Sandoz Investigational Site
    Mostar, Bosnia and Herzegovina
  • Sandoz Investigational Site
    Sarajevo, Bosnia and Herzegovina
  • Sandoz Investigational Site
    Tuzla, Bosnia and Herzegovina
  • Sandoz Investigational Site
    Barretos, Brazil
  • Sandoz Investigational Site
    Belo Horizonte, Brazil
  • Sandoz Investigational Site
    Canoas, Brazil
  • Sandoz Investigational Site
    Caxias do Sul, Brazil
  • Sandoz Investigational Site
    Curitiba, Brazil
  • Sandoz Investigational Site
    Florianópolis, Brazil
  • Sandoz Investigational Site
    Fortaleza, Brazil
  • Sandoz Investigational Site
    Itajaí, Brazil
  • Sandoz Investigational Site
    Porto Alegre, Brazil
  • Sandoz Investigational Site
    Porto Velho, Brazil
  • Sandoz Investigational Site
    Salvador, Brazil
  • Sandoz Investigational Site
    São José do Rio Preto, Brazil
  • Sandoz Investigational Site
    Besançon, France
  • Sandoz Investigational Site
    Nantes, France
  • Sandoz Investigational Site
    Batumi, Georgia
  • Sandoz Investigational Site
    Tbilisi, Georgia
  • Sandoz Investigational Site
    Mainz, Germany
  • Sandoz Investigational Site
    Münster, Germany
  • Sandoz Investigational Site
    Tübingen, Germany
  • Sandoz Investigational Site
    Catanzaro, Italy
  • Sandoz Investigational Site
    Rozzano, Italy
  • Sandoz Investigational Site
    Klaipėda, Lithuania
  • Sandoz Investigational Site
    Vilnius, Lithuania
  • Sandoz Investigational Site
    George Town, Malaysia
  • Sandoz Investigational Site
    Johor Bahru, Malaysia
  • Sandoz Investigational Site
    Kuala Lumpur, Malaysia
  • Sandoz Investigational Site
    Kuching, Malaysia
  • Sandoz Investigational Site
    Malacca, Malaysia
  • Sandoz Investigational Site
    Putrajaya, Malaysia
  • Sandoz Investigational Site
    Mexico City, Mexico
  • Sandoz Investigational Site
    Oaxaca City, Mexico
  • Sandoz Investigational Site
    San Luis Potosí City, Mexico
  • Sandoz Investigational Site
    Veracruz, Mexico
  • Sandoz Investigational Site
    Chisinau, Moldova
  • Sandoz Investigational Site
    Skopje, North Macedonia
  • Sandoz Investigational Site
    Bacolod, Philippines
  • Sandoz Investigational Site
    Bucharest, Romania
  • Sandoz Investigational Site
    Cluj-Napoca, Romania
  • Sandoz Investigational Site
    Belgrade, Serbia
  • Sandoz Investigational Site
    Kamenitz, Serbia
  • Sandoz Investigational Site
    Niš, Serbia
  • Sandoz Investigational Site
    Johannesburg, South Africa
  • Sandoz Investigational Site
    Phoenix, South Africa
  • Sandoz Investigational Site
    Badalona, Spain
  • Sandoz Investigational Site
    Barcelona, Spain
  • Sandoz Investigational Site
    Cáceres, Spain
  • Sandoz Investigational Site
    Madrid, Spain
  • Sandoz Investigational Site
    Murcia, Spain
  • Sandoz Investigational Site
    Santiago de Compostela, Spain
  • Sandoz Investigational Site
    Seville, Spain
  • Sandoz Investigational Site
    Valencia, Spain
  • Sandoz Investigational Site
    Zaragoza, Spain
  • Sandoz Investigational Site
    Ankara, Turkey (Türkiye)
  • Sandoz Investigational Site
    Yüreğir, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2024 to primary completion in May 2026, 23 months.

Of 226 industry-sponsored phase 1 interventional studies under Melanoma, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 66. This study's 23 months is below that.

Counting every sponsor, half of 412 studies reached it within 49 months; a quarter within 31 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2023
First posted
Dec 1, 2023
StartActual
May 15, 2024
Primary completionActual
May 5, 2026
CompletionActual
May 5, 2026
Last update
Jul 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06153238
Lead sponsor
Sandoz
Responsible party
Sponsor
First posted
Dec 1, 2023
Start date
May 15, 2024
Primary completion
May 5, 2026
Completion
May 5, 2026
Last update
Jul 7, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion